Our T cell Antigen Coupler (TAC) platform
uses non-gene edited donor-derived “off-the-shelf”
gamma delta (γδ) T cells.

Our Allogeneic Approach

We are leveraging the power of a healthy donor’s non-gene edited γδ T
cells to help patients better fight a variety of cancer targets.

The novel benefits of
gamma delta (γδ) T cells.

γδ cells are a subset of T cells that carry TCRs composed of γ and δ chains, in contrast to the more abundant traditional T cells that express α and β TCR chains

Although relatively smaller in numbers, γδ T cells can be isolated and expanded from healthy donors in sufficient quantities for therapeutic applications

γδ T cells are naturally involved in early phases of immune responses and primed to penetrate peripheral tissues, including cancers

γδ T cells harbor innate killing abilities, which can potentiate their anti-tumor activity

γδ T cells are unlikely to induce graft-vs-host disease because the activation of their TCR is not MHC restricted

Master Cell Banks created from healthy donor γδ T cells can generate enough γδ TAC T cells to treat likely more than 50 patients

A scalable path in allogeneic T cell manufacturing, reducing time to therapy.

We have a unique engineering strategy for developing TAC γδ T cells at commercial scale. To facilitate GMP readiness, we employ four key initiatives: identification of optimal healthy cell donors, culture optimization to obtain a high concentration of γδ cells, bioassay development to validate TAC-γδ cell products, and process optimization in bioreactors.

In developing a consistent process, we seek to generate highly pure and potent master cell banks for highly efficacious TAC products.

How it works

Sample
Collection

Extract γδ T cell samples from healthy donors.

Activation & Transduction

Genetically engineer the γδ T cells with our TAC technology with quality and transduction efficiency comparable to autologous products.

Expansion & Formulation

Significantly expand the number of γδ TAC T-cells to obtain optimal cell dose.

Cell Bank Storage

The cell product is then frozen and placed in an off-the-shelf cell bank for use when needed.

Administration

Administer TAC-γδ cells to patients in a single dose.

Treatment

Upon binding to cancer cells, the TAC-T cells should activate natural TCR signaling pathways to effectively destroy the tumor.

Sample
Collection

Extract γδ T cell samples from healthy donors.

Activation & Transduction

Genetically engineer the γδ T cells with our TAC technology with quality and transduction efficiency comparable to autologous products.

Expansion & Formulation

Significantly expand the number of γδ TAC T-cells to obtain optimal cell dose.

Cell Bank Storage

The cell product is then frozen and placed in an off-the-shelf cell bank for use when needed.

Administration

Administer TAC-γδ cells to patients in a single dose.

Treatment

Upon binding to cancer cells, the TAC-T cells should activate natural TCR signaling pathways to effectively destroy the tumor.

Promising preclinical data for multiple novel cancer targets.

In preclinical studies, allogeneic TAC-γδ cells have demonstrated an enhanced ability to eliminate Claudin 18.2-positive cancer cells. Results show that TAC-γδ cells performed comparably to our autologous standard TAC T-cells approach at a parallel development stage.

We may pursue other novel targets using an allogeneic approach, including Claudin 18.2, GPC3 and GUCY2C.